Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Sell
42
DSGN Quote, Financials, Valuation and Earnings
Last price:
$4.81
Seasonality move
:
-0.72%
Day range:
$4.67 - $5.12
52-week range:
$2.48 - $7.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.13x
Volume:
115.5K
Avg. volume:
168.3K
1-year change:
90.87%
Market cap:
$273M
Revenue:
--
EPS (TTM):
-$0.88
Analysts' Opinion
-
Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.33, Design Therapeutics has an estimated upside of 52.46% from its current price of $4.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $4.81.
Fair Value
-
According to the consensus of 2 analysts, Design Therapeutics has 52.46% upside to fair value with a price target of $7.33 per share.
DSGN vs. S&P 500
-
Over the past 5 trading days, Design Therapeutics has underperformed the S&P 500 by -10.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Design Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Design Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Design Therapeutics reported revenues of --.
Earnings Growth
-
Design Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Design Therapeutics reported earnings per share of -$0.24.
Enterprise value:
27.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$67.6M | -$78.2M | -$62.4M | -$15.1M | -$16.7M | |
| EBITDA | -$67.2M | -$77.7M | -$61.8M | -$15M | -$16.5M | |
| Diluted EPS | -$1.14 | -$1.20 | -$0.88 | -$0.21 | -$0.24 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $36.2M | $385.4M | $335.1M | $284.6M | $248M | |
| Total Assets | $36.5M | $390.6M | $341.1M | $289.6M | $252.1M | |
| Current Liabilities | $2.3M | $5.3M | $10.8M | $9.6M | $8.5M | |
| Total Liabilities | $47.8M | $8.4M | $13.8M | $12M | $10M | |
| Total Equity | -$11.3M | $382.1M | $327.3M | $277.7M | $242.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.3M | -$58.6M | -$43.1M | -$12.8M | -$9.9M | |
| Cash From Investing | -$221M | $52.5M | $44M | $5.6M | $1.8M | |
| Cash From Financing | $235K | $724K | $513K | $501K | $263K | |
| Free Cash Flow | -$52.2M | -$58.8M | -$43.4M | -$12.8M | -$9.9M | |
DSGN
Sector
Market Cap
$273M
$37.4M
Price % of 52-Week High
61.91%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
90.87%
-38.36%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.94
200-day SMA
Sell
Level
$4.96
Bollinger Bands (100)
Sell
Level
4.63 - 6.19
Chaikin Money Flow
Sell
Level
-11.9M
20-day SMA
Buy
Level
$4.79
Relative Strength Index (RSI14)
Sell
Level
49.65
ADX Line
Buy
Level
12.16
Williams %R
Neutral
Level
-49.6732
50-day SMA
Sell
Level
$4.85
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Sell
Level
-6.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Stock Forecast FAQ
In the current month, DSGN has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The DSGN average analyst price target in the past 3 months is $7.33.
-
Where Will Design Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Design Therapeutics share price will rise to $7.33 per share over the next 12 months.
-
What Do Analysts Say About Design Therapeutics?
Analysts are divided on their view about Design Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Design Therapeutics is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Design Therapeutics's Price Target?
The price target for Design Therapeutics over the next 1-year time period is forecast to be $7.33 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is DSGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Design Therapeutics is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DSGN?
You can purchase shares of Design Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Design Therapeutics shares.
-
What Is The Design Therapeutics Share Price Today?
Design Therapeutics was last trading at $4.81 per share. This represents the most recent stock quote for Design Therapeutics. Yesterday, Design Therapeutics closed at $4.81 per share.
-
How To Buy Design Therapeutics Stock Online?
In order to purchase Design Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
49
SRPT alert for Mar 19
Sarepta Therapeutics [SRPT] is up 8.8% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is up 4.99% over the past day.
Buy
93
ESLT alert for Mar 19
Elbit Systems [ESLT] is up 0.6% over the past day.
